Posts by Immunexpress
MSN: Transforming sepsis care: How host-response technology enables rapid, actionable diagnosis
From the MSN article by Omar Alhassan Sepsis remains one of the most urgent clinical emergencies in modern healthcare. Each hour of delayed targeted treatment significantly increases patient mortality. For decades, intensive care and emergency clinicians have struggled with the critical challenge of distinguishing sepsis from non-infectious systemic inflammation. Conventional culture tests take days, and…
Read MoreSequential Application of Time-Stratified Demographic, Vital, Clinical–Laboratory, and Microbiology Variables for Accurate and Rapid Identification of Sepsis
From MDPI Diseases Abstract Background: Accurate early identification of sepsis remains a major clinical challenge due to its heterogeneous presentation and overlap of clinical signs with the non-infectious systemic inflammatory response syndrome (SIRS). Timely differentiation is crucial for improving patient outcomes, meeting sepsis bundle requirements and reducing inappropriate antimicrobial use. We hypothesized that clinical–laboratory data…
Read MoreNew Publication Supports the Role of SeptiCyte® RAPID To Improve Infection Diagnosis in Post Surgery and Trauma Patients
The study demonstrates strong performance distinguishing infection from sterile inflammation in post-op and trauma patients, when routine tests aren’t reliable. SEATTLE, WA, UNITED STATES, September 2, 2026 /EINPresswire.com/ — Immunexpress, a molecular diagnostics company focused on improving outcomes for patients with suspected sepsis, today announced the publication of a new study which highlights the potential of SeptiCyte® RAPID to address…
Read MoreValidation of SeptiCyte RAPID to Discriminate Sepsis From Noninfectious Systemic Inflammation in Critically Ill Children
From the Pediatric Critical Care Medicine article Conclusions: SeptiCyte RAPID demonstrated similar performance characteristics in children to that previously reported for adults. Additional real world effectiveness studies are warranted to determine real-time clinical utility, patient benefits, and health economic impact. Source: Pediatric Critical Care Medicine on PubMed
Read MoreDiagnostics: Ruling In and Ruling Out Sepsis Using Likelihood Ratios of a Host Response Assay
From the Diagnostics publication on MDPI Overview: SeptiCyte RAPID is an FDA-cleared gene expression test that quantifies host immune response to aid in the diagnosis of sepsis. The test yields a score (the SeptiScore) ranging from 0–15, distributed across four bands (1–4) based on increased likelihood of sepsis. Each band can be characterized by average…
Read MoreImmunexpress Presenting at the Society of Critical Care Medicine (SCCM) 2026 Critical Care Congress Showing SeptiCyte RAPID® High Correlation with Blood Culture Positive Sepsis Patients
SEATTLE and BRISBANE, Australia, March 23, 2026 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced its participation, including the presentation of a poster, at the Society of Critical Care Medicine (SCCM) 2026 Critical Care Congress in Chicago, Illinois, from March 22-24th 2026. Immunexpress Chief Medical Officer Dr.…
Read MoreJournal of Clinical Medicine: Likelihood of Blood Culture Positivity Using SeptiCyte RAPID
Abstract Background: Early diagnosis and identification of causative pathogens using blood culture in patients suspected of blood stream infection (BSI) and sepsis are critical for improving patient outcomes through earlier and more targeted treatment. There is a need for tools that can guide the use of microbiologic diagnostics, especially where resources are limited, such as…
Read MoreImmunexpress Announces Publication Demonstrating SeptiCyte RAPID® Utility for Differentiating Infection from Sterile Inflammation in Readmitted Bone Marrow Transplant Patients with Febrile Neutropaenia
Study supports utility of host-response testing in febrile neutropenia patients with haematological malignancies which may be the only indication of severe underlying infections SEATTLE and BRISBANE, Australia, Feb. 25, 2026 /PRNewswire/ — Immunexpress, a molecular diagnostics company focused on improving outcomes for patients with suspected sepsis, today announced the publication of a new study demonstrating…
Read MoreDiagnostic accuracy of septicyte rapid to discriminate sepsis from non-infectious critical illness in patients meeting sepsis criteria according to sepsis-3 definition at icu admission
Download the paper as a PDF Abstract Objectives The aim of this study was to validate the SeptiCyte® RAPID assay, a molecular test to distinguish sepsis from sterile inflammation, by determining its diagnostic accuracy in critically ill patients who meet criteria for sepsis according to Sepsis-3 definition on ICU admission Design This is an observational,…
Read MoreImmunexpress Announces Publication Showing SeptiCyte RAPID® Identifies Septic Patients Most Likely to Have Positive Blood Cultures
Publication highlights strong association between a patient’s sepsis risk and likelihood of positive cultures, with SeptiCyte RAPID results just 90 minutes after a blood draw SEATTLE and BRISBANE, Australia, Feb. 12, 2026 /PRNewswire/ — Immunexpress, a molecular diagnostics company focused on improving outcomes for patients with suspected sepsis, today announced the publication of a new multi-center…
Read More